EU Panel Backs Damoctocog Alfa Pegol for Hemophilia A

Troy Brown, RN

September 24, 2018

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted to recommend damoctocog alfa pegol (Jivi, Bayer AG) for the treatment and prophylaxis of bleeding in patients aged 12 years and older who have been previously treated for hemophilia A, a congenital factor VIII deficiency.

The European Commission granted orphan medicinal product designation to damoctocog alfa pegol on February 23, 2011.

Damoctocog alfa pegol is a recombinant human factor VIII, which replaces the missing coagulation factor VIII necessary to stop bleeding. It will be marketed as powder and solvent for injectable solution (250 IU, 500 IU, 1000 IU, 2000 IU, and 3000 IU).

The US Food and Drug Administration (FDA) approved damoctocog alfa pegol for the same indication on August 30, 2018. "The initial recommended prophylactic regimen for Jivi is twice weekly with the ability to dose every 5 days and further individually adjust to less or more frequent dosing based on bleeding episodes. The FDA also approved Jivi for on-demand treatment and the perioperative management of bleeding in the same population," Bayer said in its news release about the FDA approval.

According to the EMA summary of opinion, clinical trials that showed damoctocog alfa pegol prevented and controlled bleeding "when used on demand and during surgical procedures" in adults and children with hemophilia A.

The most frequently seen adverse effects are hypersensitivity, insomnia, headache, dizziness, cough, abdominal pain, nausea, vomiting, skin redness, rash, infusion site reactions, and fever.

Only physicians experienced in treating hemophilia should prescribe damoctocog alfa pegol, according to the EMA.

The summary of product characteristics will include detailed recommendations for use of the product and will be published in the European public assessment report, which will be made available in all official European Union languages after the European Commission grants marketing authorization.

For more news, join us on Facebook and Twitter


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.